Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYTX Kyverna Therapeutics	$3.54 +2.0%	$3.44	$1.78 ▼ $8.78	$150.06M	3.05	232,736 shs	256,816 shs
MAAQ Mana Capital Acquisition	$3.74 +7.5%	$4.03	$5.35 ▼ $10.25	$30.39M	N/A	33,075 shs	56,344 shs
PLX Protalix BioTherapeutics	$1.52 -5.6%	$1.49	$0.89 ▼ $3.10	$121.00M	-0.21	847,167 shs	933,668 shs
UPXI Upexi	$7.90 +0.9%	$6.60	$1.90 ▼ $22.57	$699.70M	-0.52	12.90 million shs	10.58 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYTX Kyverna Therapeutics	+2.02%	+6.95%	-7.33%	+52.59%	-47.56%
MAAQ Mana Capital Acquisition	0.00%	-5.08%	-9.88%	-6.50%	+790.48%
PLX Protalix BioTherapeutics	-5.59%	+0.66%	+10.14%	-8.98%	+63.44%
UPXI Upexi	+0.89%	+41.83%	+51.92%	-22.47%	+94.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KYTX Kyverna Therapeutics	2.9265 of 5 stars	3.6	2.0	0.0	0.0	3.8	1.7	0.6
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	3.392 of 5 stars	3.5	2.0	0.0	0.0	3.3	1.7	1.9
UPXI Upexi	3.0083 of 5 stars	3.8	2.0	0.0	0.0	3.2	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KYTX Kyverna Therapeutics	3.17	Buy	$15.60	340.68% Upside
MAAQ Mana Capital Acquisition	0.00	N/A	N/A	N/A
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	886.84% Upside
UPXI Upexi	3.50	Strong Buy	$15.50	96.20% Upside

Current Analyst Ratings Breakdown

Latest MAAQ, PLX, KYTX, and UPXI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/4/2025	UPXI Upexi	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/16/2025	UPXI Upexi	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$16.00
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KYTX Kyverna Therapeutics	$7.03M	21.78	N/A	N/A	$4.26 per share	0.83
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	$59.76M	2.02	$0.09 per share	17.80	$0.47 per share	3.23
UPXI Upexi	$26M	27.15	N/A	N/A	$6.24 per share	1.27

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KYTX Kyverna Therapeutics	-$127.48M	-$3.68	N/A	N/A	N/A	N/A	-64.98%	-56.17%	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.90	N/A	-21.03%	-30.89%	-11.74%	N/A
UPXI Upexi	-$23.66M	N/A	0.00	∞	N/A	-135.86%	-535.19%	-122.94%	9/29/2025 (Estimated)

Latest MAAQ, PLX, KYTX, and UPXI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	KYTX Kyverna Therapeutics	-$1.00	-$0.97	+$0.03	-$0.97	N/A	N/A
5/16/2025	Q1 2025	UPXI Upexi	N/A	-$2.87	N/A	-$2.87	N/A	$3.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KYTX Kyverna Therapeutics	N/A	5.39	7.44
MAAQ Mana Capital Acquisition	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	1.98	1.27
UPXI Upexi	0.31	0.37	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KYTX Kyverna Therapeutics	18.08%
MAAQ Mana Capital Acquisition	68.44%
PLX Protalix BioTherapeutics	16.53%
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
KYTX Kyverna Therapeutics	22.00%
MAAQ Mana Capital Acquisition	N/A
PLX Protalix BioTherapeutics	6.50%
UPXI Upexi	31.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KYTX Kyverna Therapeutics	96	43.25 million	33.71 million	Optionable
MAAQ Mana Capital Acquisition	1	8.13 million	N/A	Not Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
UPXI Upexi	130	89.36 million	61.12 million	Optionable

MAAQ, PLX, KYTX, and UPXI Headlines

Recent News About These Companies

Upexi establishes Advisory Committee, welcomes Hayes as first member

August 13 at 3:39 AM | msn.com

Former Amazon aggregator turns to Solana, records $70K in daily rewards

August 13 at 3:39 AM | msn.com

Upexi (NASDAQ:UPXI) Sees Unusually-High Trading Volume - Time to Buy?

August 12 at 3:43 PM | marketbeat.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)

August 11, 2025 | prnewswire.com

Upexi (NASDAQ:UPXI) Shares Up 14.2% - Here's What Happened

August 9, 2025 | marketbeat.com

Crypto Currents: SEC eases staking rules as bitcoin miners pivot to AI

August 6, 2025 | msn.com

Alliance Global Partners Begins Coverage on Upexi (NASDAQ:UPXI)

August 6, 2025 | americanbankingnews.com

Upexi Surpasses 2 Million SOL in its Treasury

August 5, 2025 | taiwannews.com.twT

Solana Treasury Company Upexi Surpasses 2M in SOL Holdings

August 5, 2025 | coindesk.com

Upexi (NASDAQ:UPXI) Earns Buy Rating from Analysts at Alliance Global Partners

August 5, 2025 | marketbeat.com

Upexi, Inc. (NASDAQ:UPXI) Director Gene Salkind Buys 20,243 Shares

July 31, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 20,243 Shares of Stock

July 31, 2025 | insidertrades.com

Upexi (NASDAQ:UPXI) Stock Price Down 9.9% - What's Next?

July 31, 2025 | marketbeat.com

Upexi to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on August 12th-14th

July 30, 2025 | manilatimes.netM

Upexi Secures $500M Equity Deal to Buy More Solana Despite Stock Drop

July 30, 2025 | thecurrencyanalytics.comT

Upexi enters $500M equity line agreement

July 29, 2025 | msn.com

Upexi, Inc. Announces $500 Million Equity Line Agreement with A.G.P. to Accelerate the Growth of its Solana Treasury Strategy

July 29, 2025 | manilatimes.netM

Solana Treasury firm Upexi secures $500M to acquire more SOL

July 29, 2025 | msn.com

Upexi (NASDAQ:UPXI) Shares Gap Up - Here's Why

July 28, 2025 | marketbeat.com

Traders Buy Large Volume of Call Options on Upexi (NASDAQ:UPXI)

July 28, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 4,000 Shares of Stock

July 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAAQ, PLX, KYTX, and UPXI Company Descriptions

Kyverna Therapeutics NASDAQ:KYTX

$3.54 +0.07 (+2.02%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$3.54 0.00 (0.00%)

As of 08/14/2025 04:10 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Mana Capital Acquisition NASDAQ:MAAQ

$3.74 +0.26 (+7.47%)

As of 08/12/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

Protalix BioTherapeutics NYSE:PLX

$1.52 -0.09 (-5.59%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.04 (-2.37%)

As of 04:36 AM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Upexi NASDAQ:UPXI

$7.90 +0.07 (+0.89%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$7.88 -0.02 (-0.25%)

As of 06:19 AM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time